Vol 9 (August 30, 2026): Annals of Pancreatic Cancer

Editorial Commentary 
Incremental innovation in endoscopic ultrasound-guided biopsy: does the tip make the difference?
Sharon Pan, Vaibhav Wadhwa
Annals of Pancreatic Cancer  
2026;
9:
25
.
Editorial Commentary 
Engineered exosomes silence oncogenic KRASG12D and awaken immunity in pancreatic cancer
Raul A. Urrutia, Madeline Dzikowski, Gwen Lomberk
Annals of Pancreatic Cancer  
2026;
9:
24
.
Editorial Commentary 
Remodeling of tumour microenvironment of pancreatic cancer: can agonistic anti-CD40 antibodies give a new direction?
Eric C. H. Lai, Aidan K. Y. Ung
Annals of Pancreatic Cancer  
2026;
9:
23
.
Editorial Commentary 
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: interpreting the AGICC study
Daire Hanna, David Propper
Annals of Pancreatic Cancer  
2026;
9:
22
.
Editorial Commentary 
Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies
Ahmed Abdelhakeem, Hani M. Babiker
Annals of Pancreatic Cancer  
2026;
9:
21
.
Editorial Commentary 
18F-prostate specific membrane antigen positron emission tomography/computed tomography for pancreatic ductal adenocarcinoma: not specific enough
Eric M. Turner, David S. Summerlin, Carli E. Calderone, Elainea N. Smith, Samuel J. Galgano
Annals of Pancreatic Cancer  
2026;
9:
20
.
Editorial Commentary 
Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance
Nayef Abdel-Razeq, Debabrata Mukhopadhyay, Hani Babiker
Annals of Pancreatic Cancer  
2026;
9:
19
.
Case Report 
ATP1B1::PRKACA fusion-defined intraductal oncocytic papillary neoplasm of the pancreas: a case report
Gregory Furletti, David Park, Kathryn LaRusso, Erin Meslar, Thomas Fishbein, Rashmi Samdani
Annals of Pancreatic Cancer  
2026;
9:
17
.